Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective

BACKGROUND: Surgical resection has remained the mainstay of treatment of GIST with a 5-year-survival of 28–35%. Tyrosine kinase inhibitor (Imatinib) has revolutionised the treatment of these tumours. The current research is directed towards expanding the role of this drug in the treatment of GIST. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Date, Ravindra S, Stylianides, Nicholas A, Pursnani, Kishore G, Ward, Jeremy B, Mughal, Muntzer M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491627/
https://www.ncbi.nlm.nih.gov/pubmed/18644105
http://dx.doi.org/10.1186/1477-7819-6-77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491627/
https://www.ncbi.nlm.nih.gov/pubmed/18644105
http://dx.doi.org/10.1186/1477-7819-6-77

Ejemplares similares